These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19678753)

  • 1. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.
    Freedman MS; Cohen B; Dhib-Jalbut S; Jeffery D; Reder AT; Sandberg-Wollheim M; Weinstock-Guttman B
    Curr Med Res Opin; 2009 Oct; 25(10):2459-70. PubMed ID: 19678753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cognitive impairment in patients with multiple sclerosis.
    Patti F
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1679-99. PubMed ID: 22876911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
    Karussis D; Biermann LD; Bohlega S; Boiko A; Chofflon M; Fazekas F; Freedman M; Gebeily S; Gouider R; Havrdova E; Jakab G; Karabudak R; Miller A;
    Eur J Neurol; 2006 Jan; 13(1):61-71. PubMed ID: 16420394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlapping and distinct mechanisms of action of multiple sclerosis therapies.
    Graber JJ; McGraw CA; Kimbrough D; Dhib-Jalbut S
    Clin Neurol Neurosurg; 2010 Sep; 112(7):583-91. PubMed ID: 20627553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pediatric multiple sclerosis and variants.
    Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
    Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairment in multiple sclerosis.
    Patti F
    Mult Scler; 2009 Jan; 15(1):2-8. PubMed ID: 18805842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of MS.
    Vosoughi R; Freedman MS
    Clin Neurol Neurosurg; 2010 Jun; 112(5):365-85. PubMed ID: 20362388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of multiple sclerosis in children and adolescents.
    Tenembaum SN
    Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multiple sclerosis: characteristics and management.
    Hawker K
    Neurol Clin; 2011 May; 29(2):423-34. PubMed ID: 21439451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis.
    Zhang J; Hutton G
    Annu Rev Med; 2005; 56():273-302. PubMed ID: 15660513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain health: time matters in multiple sclerosis.
    Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
    Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.